I make a donation

APTITUDE

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor

Terminée

Remerciements de la Famille COLLET

Prix de Recherche Pr Jean-Philippe COLLET

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

objectif

Monocentric, biological, prospective, ex-vivo, trial aiming at comparing the effects of in vivo platelet transfusion on platelet activation in patients with bleeding caused by aorto-coronary bypass, depending on the type of inhibitor of the P2Y12 receptor (clopidogrel, prasugrel or ticagrelor) and the effects of ex-vivo transfusion with un-treated PRP on the normalisation of the platelet reactivity in SCA/PCI patients after a dosis of clopidogrel, prasugrel ou ticagrelor.

date de réalisation

2014

nombre de patients

nombre de centres participants

Monocentric (Pitié-Salpêtrière)

type de financement

Public (INSERM) and private (ACTION Group)

Référence

n°301111, CNIL n°1547216v0

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study

Publication

Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P₂Y₁₂ inhibition by clopidogrel, prasugrel, and ticagrelor : the APTITUDE study
Stephen A O'Connor, Julien Amour, Anne Mercadier, Réjane Martin, Mathieu Kerneis, Jérémie Abtan, Delphine Brugier, Johanne Silvain, Olivier Barthélémy, Pascal Leprince, Gilles Montalescot, Jean-Philippe Collet, ACTION Study Group
Publicated in Circulation : Cardiovascular Interventions

Autres études

AFLOAT

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.

EDUC-DAI

En cours

Impact of therapeutic education on the quality of life and the anxiety of patients with a defibrillator.

AFLOAT

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.